Biotech Daily — Dr Boreham’s Crucible: Imagion Biosystems

Dec 21, 2021
Posted in: News, Investor updates, Press & Media

Home » Biotech Daily — Dr Boreham’s Crucible: Imagion Biosystems

Biotech Daily — Dr Boreham’s Crucible: Imagion Biosystems

Dec 21, 2021
Posted in: News, Investor updates, Press & Media

Tim Boreham revisits Imagion Biosystems’ potential in this 5-1/2 page article profiling the company and discussing its recent milestones.

Read the article here.

Imagion Biosystems HER2 Breast Cancer Program Update

October 7, 2025

Key Highlights: Manufacturing of the MagSense® HER2 Breast Cancer Imaging Agent for the Phase 2 clinical trial has been completed – major milestone achieved IBX,

Imagion Biosystems EGM Chairman’s Address

September 24, 2025

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging

Pitt Street Research – “Detecting cancers earlier” with Imagion Biosystems

September 11, 2025

Imagion Biosystems (ASX: IBX) is at a pivotal point of its history, about to take its MagSense technology into Phase 2. Abstract: MagSense is a

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Biotech Daily — Dr Boreham’s Crucible: Imagion Biosystems

Biotech Daily — Dr Boreham’s Crucible: Imagion Biosystems

Related Articles

Imagion Biosystems HER2 Breast Cancer Program Update

Imagion Biosystems EGM Chairman’s Address

Pitt Street Research – “Detecting cancers earlier” with Imagion Biosystems

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list